Yi Lin

MD, PhD

Mayo Clinic

Yi Lin, MD, PhD, is a Consultant in Hematology/Oncology at the Mayo Clinic in Rochester, Minnesota, where she is chair of the Cellular Therapeutics Cross-Disciplinary Group. She also has a clinical practice in lymphoid malignancy and research program in cellular immunotherapy

She completed her medical training at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, before completing a residency at the Mayo Clinic College of Medicine.

Dr Lin’s research focuses on cellular therapy, CAR T-cells, cancer vaccination, immunotherapy, myeloma, lymphoma, and amyloidosis.

CAR-T in myeloma: KarMMa and CRB-402 updates

CAR-T in myeloma: KarMMa and CRB-402 updates

Yi Lin • 6 Dec 2019

LEGEND-2 and CARTITUDE-1: anti-BCMA CAR-T for myeloma

LEGEND-2 and CARTITUDE-1: anti-BCMA CAR-T for myeloma

Yi Lin • 6 Dec 2019

Correlation of peak lymphocyte count after axi-cel and clinical response in lymphoma

Correlation of peak lymphocyte count after axi-cel and clinical response in lymphoma

Yi Lin • 6 Dec 2019

Real world data for axi-cel in lymphoma with secondary CNS involvement

Real world data for axi-cel in lymphoma with secondary CNS involvement

Yi Lin • 8 Dec 2019

CAR T-cell therapy in myeloma

CAR T-cell therapy in myeloma

Edward Stadtmauer et al. • 11 Oct 2019

CAR T-cells for MM: where are we going?

CAR T-cells for MM: where are we going?

Yi Lin • 15 Jun 2019

CAR-T treatment outcomes: MM real-world data

CAR-T treatment outcomes: MM real-world data

Yi Lin • 13 Jun 2019

Treatment challenges in myeloma

Treatment challenges in myeloma

Managing patients that have undergone CAR T-cell therapy

Managing patients that have undergone CAR T-cell therapy

$Durable remission at 2 years following CAR-T axi-cel in refractory DLBCL$ 1:22

Durable remission at 2 years following CAR-T axi-cel in refractory DLBCL

Yi Lin • 2 Dec 2018

CAR T-cell updates in lymphoma and myeloma from ASH 2018

Anti-BCMA CAR T-cells in myeloma: what data do we have so far?

Anti-BCMA CAR T-cells in myeloma: what data do we have so far?

Yi Lin • 7 Sep 2018

ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel

ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel

Yi Lin • 9 Dec 2017

Prophylactic treatment for CAR T-cell toxicity shows promising results

Prophylactic treatment for CAR T-cell toxicity shows promising results

Yi Lin • 9 Dec 2017

Next-generation CAR T-cell products for 2018

Next-generation CAR T-cell products for 2018

Yi Lin • 9 Dec 2017

Anti-BCMA CAR T-cells for MM: durable clinical responses with bb2121

Anti-BCMA CAR T-cells for MM: durable clinical responses with bb2121

Yi Lin • 9 Dec 2017